567 related articles for article (PubMed ID: 24528057)
81. Diagnostic value of pleural effusion Krebs von den Lungen-6 in malignant pleural effusion of patients with non-small cell lung cancer.
Wang J; Ling L; Chen S; Chou L; Wang Y; Hu L
Lab Med; 2024 May; 55(3):271-276. PubMed ID: 37566516
[TBL] [Abstract][Full Text] [Related]
82. Predicting Malignant and Paramalignant Pleural Effusions by Combining Clinical, Radiological and Pleural Fluid Analytical Parameters.
Herrera Lara S; Fernández-Fabrellas E; Juan Samper G; Marco Buades J; Andreu Lapiedra R; Pinilla Moreno A; Morales Suárez-Varela M
Lung; 2017 Oct; 195(5):653-660. PubMed ID: 28656381
[TBL] [Abstract][Full Text] [Related]
83. Evaluation of pleural fluid survivin and XIAP for the diagnosis of malignant pleural effusion.
Li J; Li ZN; Bao QL; Ge LP; Li XQ; Chen P
Tumour Biol; 2012 Oct; 33(5):1803-10. PubMed ID: 22696161
[TBL] [Abstract][Full Text] [Related]
84. Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions.
Passebosc-Faure K; Li G; Lambert C; Cottier M; Gentil-Perret A; Fournel P; Pérol M; Genin C
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6862-7. PubMed ID: 16203775
[TBL] [Abstract][Full Text] [Related]
85. Elevated Hsp90-beta contributes to differential diagnosis of pleural effusion caused by lung cancer and correlates with malignant biological behavior of lung cancer.
Biaoxue R; Min L; Tian F; Wenlong G; Hua L
BMC Pulm Med; 2018 Dec; 18(1):188. PubMed ID: 30522463
[TBL] [Abstract][Full Text] [Related]
86. Diagnostic value of tumor markers for differentiating malignant and benign pleural effusions of Iranian patients.
Ghayumi SM; Mehrabi S; Doroudchi M; Ghaderi A
Pathol Oncol Res; 2005; 11(4):236-41. PubMed ID: 16388321
[TBL] [Abstract][Full Text] [Related]
87. Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies.
Fuhrman C; Duche JC; Chouaid C; Abd Alsamad I; Atassi K; Monnet I; Tillement JP; Housset B
Clin Biochem; 2000 Jul; 33(5):405-10. PubMed ID: 11018693
[TBL] [Abstract][Full Text] [Related]
88. Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer.
Lu GJ; Shao CJ; Zhang Y; Wei YY; Xie WP; Kong H
Oncotarget; 2017 Jul; 8(30):49217-49223. PubMed ID: 28514746
[TBL] [Abstract][Full Text] [Related]
89. Study on the application of percutaneous closed pleural brushing combined with cell block technique in the diagnosis of malignant pleural effusion.
Wang K; Hu X; Chen Y; Yi X; Han X; Zhu D; Zhu B; Luo H
Clin Respir J; 2024 Jan; 18(1):e13705. PubMed ID: 37775991
[TBL] [Abstract][Full Text] [Related]
90. Diagnostic usefulness of tumour marker levels in pleural effusions of malignant and benign origin.
Kuralay F; Tokgöz Z; Cömlekci A
Clin Chim Acta; 2000 Oct; 300(1-2):43-55. PubMed ID: 10958862
[TBL] [Abstract][Full Text] [Related]
91. The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion.
Dejmek A; Hjerpe A
Diagn Cytopathol; 2005 Mar; 32(3):160-6. PubMed ID: 15690331
[TBL] [Abstract][Full Text] [Related]
92. Diagnostic value of tumour markers in pleural effusions.
Volarić D; Flego V; Žauhar G; Bulat-Kardum L
Biochem Med (Zagreb); 2018 Feb; 28(1):010706. PubMed ID: 29472801
[TBL] [Abstract][Full Text] [Related]
93. The diagnostic value of pleural fluid homocysteine in malignant pleural effusion.
Santotoribio JD; Del Valle-Vazquez L; García-de la Torre A; Del Castillo-Otero D; Lopez-Saez JB; Sanchez Del Pino MJ
PLoS One; 2019; 14(9):e0222616. PubMed ID: 31550262
[TBL] [Abstract][Full Text] [Related]
94. The diagnostic value of CEA for lung cancer-related malignant pleural effusion in China: a meta-analysis.
Cheng C; Yang Y; Yang W; Wang D; Yao C
Expert Rev Respir Med; 2022 Jan; 16(1):99-108. PubMed ID: 34112035
[TBL] [Abstract][Full Text] [Related]
95. Is neuron-specific enolase useful for diagnosing malignant pleural effusions? evidence from a validation study and meta-analysis.
Zhu J; Feng M; Liang L; Zeng N; Wan C; Yang T; Shen Y; Wen F
BMC Cancer; 2017 Aug; 17(1):590. PubMed ID: 28854885
[TBL] [Abstract][Full Text] [Related]
96. Serum levels of tumor markers and their clinical significance in epithelial ovarian cancer.
Shan D; Cheng S; Ma Y; Peng H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Jul; 48(7):1039-1049. PubMed ID: 37724407
[TBL] [Abstract][Full Text] [Related]
97. Prognostic values of normal preoperative serum cancer markers for gastric cancer.
Feng F; Sun L; Liu Z; Liu S; Zheng G; Xu G; Guo M; Lian X; Fan D; Zhang H
Oncotarget; 2016 Sep; 7(36):58459-58469. PubMed ID: 27533455
[TBL] [Abstract][Full Text] [Related]
98. Diagnostic utility of pleural fluid and serum markers in differentiation between malignant and non-malignant pleural effusions.
Korczynski P; Krenke R; Safianowska A; Gorska K; Abou Chaz MB; Maskey-Warzechowska M; Kondracka A; Nasilowski J; Chazan R
Eur J Med Res; 2009 Dec; 14 Suppl 4(Suppl 4):128-33. PubMed ID: 20156743
[TBL] [Abstract][Full Text] [Related]
99. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
100. CA 72-4 radioimmunoassay in the diagnosis of malignant effusions. Comparison of various tumor markers.
Ferroni P; Szpak C; Greiner JW; Simpson JF; Guadagni F; Johnston WW; Colcher D
Int J Cancer; 1990 Sep; 46(3):445-51. PubMed ID: 2394511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
